新型インフルエンザワクチン市場- 世界の産業規模、シェア、動向、機会、予測、投与経路別、ブランドタイプ別、流通チャネル別、地域別セグメント、競合、2020年～2030年

新型インフルエンザワクチンの世界市場規模は2024年に99億1,000万米ドルとなり、2030年までの予測期間のCAGRは4.23%で、目覚ましい成長が予測されています。

新型インフルエンザワクチンの世界市場は、主に豚インフルエンザとして一般的に知られているH1N1インフルエンザウイルスの予防と蔓延抑制に焦点を当てたヘルスケア産業の重要な構成要素です。新型インフルエンザワクチンの世界市場は、インフルエンザ流行の増加やワクチン接種プログラムに対する意識の高まりなど、複数の要因によって牽引されています。世界中の政府やヘルスケア機関は、季節性インフルエンザやパンデミックインフルエンザを予防するために予防接種の取り組みに投資しており、新型インフルエンザワクチンの需要を促進しています。新型インフルエンザ感染によって重篤な合併症を引き起こしやすい高齢者人口の増加が、市場の成長をさらに後押ししています。例えば、2023年10月に発表されたCDCの推計によると、季節性インフルエンザの症例は世界中で10億件近く発生しており、そのうち約300万～500万件が重症に分類されています。サーベイランスの強化や、流通・供給・投与の監視に重点を置いた、国レベルでも世界レベルでもワクチン接種に対する政府の強力な支援は、市場成長を促進する重要な要因です。

組み換えワクチンやアジュバントワクチンを含むワクチン開発の進歩が有効性を高め、普及を促進。新型H1N1ウイルス株の出現により、ワクチンの継続的な更新が必要となり、市場の拡大を後押ししています。研究開発活動の活発化、WHOやCDCなどの世界保健機関からの資金援助、製薬企業間の戦略的提携は、ワクチンの迅速な開発と流通に貢献しています。COVID-19の大流行により、呼吸器感染症に対する国民の意識が高まり、ワクチンインフラ全体が強化されました。政府による高リスク群へのインフルエンザワクチン接種義務の拡大が、有利な償還政策と相まって、市場の成長をさらに刺激しています。細胞ベースやmRNAプラットフォームを含むワクチン製造の技術的進歩は、効率性と拡張性の向上をもたらします。そのため、より広範なインフルエンザ予防を提供する混合ワクチンに対する需要の高まりが、今後数年間の技術革新と市場拡大の原動力になると予想されます。

主な市場促進要因

パンデミックへの備えと意識向上

主な市場課題

ウイルスの変異と進化

主要市場動向

汎用インフルエンザワクチン

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の新型インフルエンザワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 投与経路別（皮内ワクチン、筋肉内ワクチン、鼻腔内ワクチン）
  • ブランドタイプ別（Agripal、Fiuarix、Influgen、Influvac、Nasovac、Vaxigrip）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 製品市場マップ
  • 投与経路別
  • ブランド別
  • 流通チャネル別
  • 地域別

第6章 北米の新型インフルエンザワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の新型インフルエンザワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋地域の新型インフルエンザワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米の新型インフルエンザワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの新型インフルエンザワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• AstraZeneca PLC
• Sanofi Pasteur MSD AG
• GSK PLC
• Abbott Laboratories Inc
• CSL Ltd
• Pfizer Inc
• CPL Biologicals Pvt Ltd
• Mitsubishi Tanabe Pharma Corp
• Sinovac Biotech Co Ltd
• Zydus Lifesciences Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

Global H1N1 Vaccines Market was valued at USD 9.91 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.23% through 2030. The global H1N1 vaccines market is a crucial component of the healthcare industry, primarily focused on preventing and controlling the spread of the H1N1 influenza virus, commonly known as swine flu. The global H1N1 vaccines market is driven by multiple factors, primarily the rising prevalence of influenza outbreaks and the increasing awareness of vaccination programs. Governments and healthcare organizations worldwide are investing in immunization initiatives to prevent seasonal and pandemic influenza, fueling demand for H1N1 vaccines. The growing elderly population, which is more susceptible to severe complications from H1N1 infections, further boosts market growth. For instance, according to CDC estimates published in October 2023, nearly one billion cases of seasonal influenza occur worldwide, with approximately 3-5 million classified as severe. The increased surveillance efforts and strong government support for vaccination at both national and global levels-focusing on monitoring distribution, supply, and administration-are key factors driving market growth.

Advancements in vaccine development, including recombinant and adjuvanted vaccines, enhance efficacy and drive adoption. The emergence of new H1N1 virus strains necessitates continuous vaccine updates, supporting market expansion. Increasing R&D activities, funding from global health organizations such as the WHO and CDC, and strategic collaborations among pharmaceutical companies contribute to the rapid development and distribution of vaccines. The COVID-19 pandemic has heightened public awareness of respiratory infections, strengthening the overall vaccine infrastructure. Expanding government mandates for influenza vaccination in high-risk groups, coupled with favorable reimbursement policies, further stimulate market growth. Technological advancements in vaccine production, including cell-based and mRNA platforms, offer improved efficiency and scalability. Therefore, the rising demand for combination vaccines that provide broader influenza protection is expected to drive innovation and market expansion in the coming years.

Key Market Drivers

Pandemic Preparedness and Awareness

Pandemic preparedness and awareness play a crucial role in driving the growth of the global H1N1 vaccines market. Governments, health organizations, and pharmaceutical companies have intensified efforts to strengthen pandemic response strategies, ensuring rapid vaccine development, stockpiling, and distribution. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) continue to promote global surveillance programs, early detection systems, and public awareness campaigns, increasing the demand for H1N1 vaccines. The COVID-19 pandemic has further underscored the importance of robust vaccination programs, leading to improved healthcare infrastructure and vaccine supply chains. Growing public awareness about the risks of influenza pandemics has encouraged higher vaccination rates, particularly among vulnerable populations such as the elderly, pregnant women, and immunocompromised individuals. Governments worldwide are implementing mandatory vaccination policies for healthcare workers and high-risk groups, boosting market expansion. The pandemic preparedness initiatives have led to significant investments in vaccine research, resulting in the development of more effective and rapidly deployable H1N1 vaccines, including cell-based and mRNA-based formulations. Increased collaboration between public and private sectors has accelerated vaccine accessibility, further driving market growth. As global preparedness measures continue to evolve, the demand for H1N1 vaccines is expected to rise, ensuring better pandemic resilience. According to the World Health Organization (WHO), seasonal influenza causes approximately 3 to 5 million cases of severe illness and between 290,000 to 650,000 respiratory-related deaths annually. In industrialized countries, the majority of influenza-related deaths occur in individuals over 65 years old. Seasonal influenza can lead to a wide range of health outcomes, from mild illness to severe complications and even death.

Key Market Challenges

Virus Mutations and Evolution

Perhaps the most significant challenge in the H1N1 vaccines market is the constant evolution of the virus. H1N1 influenza strains mutate regularly, making it necessary to update vaccine formulations to match the currently circulating strains. This requires ongoing research, surveillance, and timely adjustments in vaccine production, driving the need for advanced manufacturing technologies and robust global monitoring systems. Governments and health organizations, such as the WHO and CDC, play a crucial role in identifying dominant strains and recommending vaccine updates, ensuring continued market demand. The pharmaceutical companies invest heavily in innovative vaccine platforms, such as mRNA and cell-based technologies, to enable faster production and adaptability to viral mutations. The unpredictable nature of influenza outbreaks necessitates strategic vaccine stockpiling and rapid distribution systems, further fueling market growth. As global health preparedness efforts intensify, the demand for adaptable and effective H1N1 vaccines continues to rise, supporting the expansion of the market.

Key Market Trends

Universal Influenza Vaccines

One of the most promising trends driving the growth of the global H1N1 vaccines market is the development of universal influenza vaccines. Unlike traditional seasonal flu vaccines, which require frequent updates to match circulating strains, universal vaccines aim to provide long-lasting immunity against multiple influenza subtypes, including H1N1. These vaccines target conserved regions of the virus, such as hemagglutinin stalk domains and internal viral proteins, which undergo fewer mutations compared to surface antigens. By inducing broader immune responses, universal vaccines could significantly reduce the burden of annual vaccinations and enhance pandemic preparedness. Pharmaceutical companies and research institutions are actively investing in advanced vaccine platforms, including mRNA, viral vector, and nanoparticle-based approaches, to accelerate universal vaccine development. The growing support from governments and global health organizations is further driving clinical trials and regulatory approvals. A successful universal influenza vaccine could streamline vaccine manufacturing, reducing production costs and distribution challenges. This breakthrough would be particularly beneficial for low- and middle-income countries with limited healthcare resources, improving global access to influenza prevention. As research progresses and technological advancements continue, universal influenza vaccines have the potential to transform the H1N1 vaccines market, offering a more efficient and sustainable approach to combating influenza outbreaks worldwide.

Key Market Players

• AstraZeneca PLC
• Sanofi Pasteur MSD AG
• GSK PLC
• Abbott Laboratories Inc
• CSL Ltd
• Pfizer Inc
• CPL Biologicals Pvt Ltd
• Mitsubishi Tanabe Pharma Corp
• Sinovac Biotech Co Ltd
• Zydus Lifesciences Ltd

Report Scope:

In this report, the Global H1N1 Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

H1N1 Vaccines Market, By Route of Administration:

• Intradermal Vaccines
• Intramuscular Vaccines
• Intranasal Vaccines

H1N1 Vaccines Market, By Type of Brand:

• Agripal
• Fiuarix
• Influgen
• Influvac
• Nasovac
• Vaxigrip

H1N1 Vaccines Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

H1N1 Vaccines Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global H1N1 Vaccines Market.

Available Customizations:

Global H1N1 Vaccines market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global H1N1 Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 5.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Route of Administration
  • 5.3.2. By Type of Brand
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America H1N1 Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 6.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States H1N1 Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Type of Brand
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada H1N1 Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Type of Brand
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico H1N1 Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Type of Brand
      • 6.3.3.2.3. By Distribution Channel

7. Europe H1N1 Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 7.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany H1N1 Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Type of Brand
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom H1N1 Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Type of Brand
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. France H1N1 Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Type of Brand
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy H1N1 Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Type of Brand
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain H1N1 Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Type of Brand
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific H1N1 Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 8.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China H1N1 Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Type of Brand
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Japan H1N1 Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Type of Brand
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. India H1N1 Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Type of Brand
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Australia H1N1 Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Type of Brand
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. South Korea H1N1 Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Type of Brand
      • 8.3.5.2.3. By Distribution Channel

9. South America H1N1 Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 9.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil H1N1 Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Type of Brand
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina H1N1 Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Type of Brand
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia H1N1 Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Type of Brand
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa H1N1 Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 10.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa H1N1 Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Type of Brand
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia H1N1 Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Type of Brand
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE H1N1 Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Type of Brand
      • 10.3.3.2.3. By Distribution Channel
  • 10.3.4. Kuwait H1N1 Vaccines Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Route of Administration
      • 10.3.4.2.2. By Type of Brand
      • 10.3.4.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. AstraZeneca PLC

. 14.1.1. Business Overview

• 14.1.2. Product Offerings
• 14.1.3. Recent Developments
• 14.1.4. Financials (As Reported)
• 14.1.5. Key Personnel
• 14.1.6. SWOT Analysis
• 14.2. Sanofi Pasteur MSD AG
• 14.3. GSK PLC
• 14.4. Abbott Laboratories Inc
• 14.5. CSL Ltd
• 14.6. Pfizer Inc
• 14.7. CPL Biologicals Pvt Ltd
• 14.8. Mitsubishi Tanabe Pharma Corp
• 14.9. Sinovac Biotech Co Ltd
• 14.10. Zydus Lifesciences Ltd

15. Strategic Recommendations

16. About Us & Disclaimer